US EditionFrench drug giant Sanofi plans massive US investment to counter Trump tariffs
- On May 14, 2025, French pharmaceutical leader Sanofi revealed plans to allocate a minimum of $20 billion toward expanding its manufacturing facilities and research and development efforts within the United States through 2030.
- Sanofi's investment responds to President Trump's executive order targeting lower drug prices and threatening tariffs to boost US pharmaceutical manufacturing.
- The plan includes increasing US research spending to accelerate science, expanding capacity at existing sites, and partnering with domestic manufacturers across multiple states.
- Sanofi’s CEO, Paul Hudson, emphasized that the company’s planned funding will be significant, supporting domestic production of essential medicines in the US and generating numerous well-paying jobs across several states.
- Sanofi's US investments join similar commitments by Roche, Eli Lilly, and others, with outcomes depending on evolving policies and potential impacts of Trump's drug pricing order.
37 Articles
37 Articles
Sanofi, CMA CGM or LVMH Are Engaging with Trump? Let's Give Them a Good Cure for Economic Patriotism!
After the CMA CGM shipping carrier, the Sanofi lab will invest 20 billion in the United States to escape customs duties. Another point given by large French companies to Donald Trump, and a marked goal against our camp.
Revealed: Pharmacists are stockpiling the most common drugs — in fear of Trump
In the dim basement of a Salt Lake City pharmacy, hundreds of amber-colored plastic pill bottles sit stacked in rows, one man’s defensive wall in a tariff war. Independent pharmacist Benjamin Jolley and his colleagues worry that the tariffs, aimed at bringing drug production to the United States, could instead drive companies out of business while raising prices and creating more of the drug shortages that have plagued American patients for seve…
kffhealthnews.org
The Gilmer MirrorPharmacists Stockpile Most Common Drugs on Chance of Targeted Trump Tariffs
In the dim basement of a Salt Lake City pharmacy, hundreds of amber-colored plastic pill bottles sit stacked in rows, one man’s defensive wall in a tariff war. Independent pharmacist Benjamin Jolley and his colleagues worry that the tariffs, aimed at bringing drug production to the United States, could instead drive companies out of business while raising prices and creating more of the drug shortages that have plagued American patients for seve…
French drug giant Sanofi plans massive US investment to counter Trump tariffs
French pharmaceutical giant Sanofi plans to invest billions of euros to expand its manufacturing in the United States, in response to President Donald Trump’s trade policies – which include threats to impose tariffs on medicines in order to increase homegrown production.
Coverage Details
Bias Distribution
- 57% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
